Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966436 | 0.93 | GAA (0.59) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL31215241 | 0.93 | GAA (0.59) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL8901237 | 0.84 | GAA (0.51) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL12190715 | 0.84 | KDM4E (0.58) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL29424850 | 0.84 | GAA (0.74) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL6473999 | 0.84 | GAA (0.74) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL11568484 | 0.82 | KDM4E (0.76) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL973441 | 0.81 | KDM4E (0.49) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL15322951 | 0.81 | KDM4E (0.50) | GAAKDM4EPOLBATMALDH1A1 | |
| SCHEMBL24501481 | 0.80 | KDM4E (0.46) | GAAKDM4EPOLBATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626354-A1 | Viral polymerase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1718608-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1718608-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050222236-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080388-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | GAA 1079/4885KDM4E 3117/4885POLB 9/4885 |
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | GAA 1620/4885KDM4E 2636/4885POLB 11/4885 |
| US-20050222236-A1 | Viral polymerase inhibitors | POLR2A, POLR1E, RPP30 | GAA 1620/4885KDM4E 2636/4885POLB 11/4885 |
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | GAA 1620/4885KDM4E 2636/4885POLB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.